TNF and inflammatory bowel disease: Approximately 30% of IBD patients do not respond to anti-TNF therapy (primary non-responders), and nearly half of those who initially benefit from these drugs experience a loss of clinical benefits within the first year, necessitating dose escalation or treatment alteration, referred to as “secondary loss of response” [20, 21].